Every indexed document

tax or regulatory proceedings or in government intelligence

including the federal money laundering statute

the FDA has not published detailed guidance about its cannabis-related enforcement

including FDA resources and threats to public health. Beyond

the FDA may consult with its federal and state

and suggests certain steps to address those challenges. The guidance

due to the unique nature of botanical drugs

Sativex or Epidiolex). The FDA publication does not demonstrate that neither

based on the FD&C Act provisions cited by the FDA

and by pursuing injunctions and criminal prosecutions.

an NDA for Epidiolex was submitted to the FDA in October 2017. If approved by

and although an NDA has not been submitted

conduct in compliance with state law is less likely to

that illegal distribution of marijuana is a serious crime which

only one cannabis cultivation site in the United States has operated with the

the DEA purportedly amended this regulatory

the CSA effectively prohibits such production in the United States without DEA

because the production of such non-marijuana

federal policies and laws recently passed by the U.S. Congress have

and general business operations (such as